In the early 1990s, methyllyconitine, a major constituent, was found to be an effective ligand for neuronal nicotinic acetylcholine receptor which prompted the scientists to find suitable natural cholinesterase inhibiters to treat cerebral dementia as well as Alzheimer’s diseases (AD) [7]. Here, BCHE is linked to Alzheimer disease.